Literature DB >> 12559797

Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts.

Christian Peters1, Yvonne Paterson.   

Abstract

Bioengineered Listeria monocytogenes can be used as a recombinant bacterial vaccine vector for the induction of strong cell-mediated immunity to passenger antigens. Listeria loses virulence after undergoing bioengineering techniques, thus decreasing its efficacy as a vaccine vector. We addressed this problem by examining the virulence, and the ability to induce CD8(+) T-cells, of Listeria monocytogenes vaccine strains before and after passaging through mice. We found that two in vivo passages are required to restore the induction of cell-mediated immunity to passenger antigens and maximum virulence to these strains. In addition, we found that after each passage, harvested bacteria must be cloned and checked for expression of the bioengineered gene to counter selection in favor of antigen loss mutants. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559797     DOI: 10.1016/s0264-410x(02)00554-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

Review 1.  Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy.

Authors:  Yvonne Paterson; Patrick D Guirnalda; Laurence M Wood
Journal:  Semin Immunol       Date:  2010-03-17       Impact factor: 11.130

Review 2.  Current state in the development of candidate therapeutic HPV vaccines.

Authors:  Andrew Yang; Jessica Jeang; Kevin Cheng; Ting Cheng; Benjamin Yang; T-C Wu; Chien-Fu Hung
Journal:  Expert Rev Vaccines       Date:  2016-03-07       Impact factor: 5.217

3.  Effect of continuous sub-culturing on infectivity of Clostridium perfringens ATCC13124 in mouse gas gangrene model.

Authors:  Ravi Bhushan Kumar; Syed Imteyaz Alam
Journal:  Folia Microbiol (Praha)       Date:  2017-02-17       Impact factor: 2.099

Review 4.  Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy.

Authors:  Alexander C Cohen; Brandon M Roane; Charles A Leath
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

5.  Listeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines.

Authors:  Thorsten Verch; Zhen-Kun Pan; Yvonne Paterson
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

6.  A DNA prime-oral Listeria boost vaccine in rhesus macaques induces a SIV-specific CD8 T cell mucosal response characterized by high levels of alpha4beta7 integrin and an effector memory phenotype.

Authors:  Paul Neeson; Jean Boyer; Sanjeev Kumar; Mark G Lewis; Lennox Mattias; Ron Veazey; David Weiner; Yvonne Paterson
Journal:  Virology       Date:  2006-08-09       Impact factor: 3.616

7.  Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression.

Authors:  Hidenobu Ishizaki; Guang-Yun Song; Tumul Srivastava; Kyla Driscoll Carroll; Vafa Shahabi; Edwin R Manuel; Don J Diamond; Joshua D I Ellenhorn
Journal:  J Immunother       Date:  2010 Jul-Aug       Impact factor: 4.456

8.  Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature.

Authors:  Paulo Cesar Maciag; Matthew M Seavey; Zhen-Kun Pan; Soldano Ferrone; Yvonne Paterson
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

9.  Live attenuated Listeria monocytogenes expressing HIV Gag: immunogenicity in rhesus monkeys.

Authors:  Shisong Jiang; Robert A Rasmussen; Katrina M Nolan; Fred R Frankel; Judy Lieberman; Harold M McClure; Kristina M Williams; Uma S Babu; Richard B Raybourne; Elizabeth Strobert; Ruth M Ruprecht
Journal:  Vaccine       Date:  2007-08-27       Impact factor: 3.641

Review 10.  The current state of therapeutic and T cell-based vaccines against human papillomaviruses.

Authors:  Andrew Yang; Emily Farmer; John Lin; T-C Wu; Chien-Fu Hung
Journal:  Virus Res       Date:  2016-12-06       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.